PRED FORTE (prednisolone acetate) by AbbVie is clinical pharmacology prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. First approved in 1973.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
PRED FORTE is a topical ophthalmic suspension containing prednisolone acetate, a potent glucocorticoid approved in 1973 for treating ocular inflammation. It works by inhibiting acute inflammatory responses including edema, fibrin deposition, and capillary dilation, with 3-5 times greater anti-inflammatory potency than hydrocortisone. The product is indicated for allergic conjunctivitis, post-operative inflammation, and other anterior segment inflammatory conditions.
Product approaching loss of exclusivity with modest Part D utilization signals declining revenue trajectory and likely reduced team investment.
CLINICAL PHARMACOLOGY Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
Study of T-PRED(TM) Compared to Pred Forte(R) II
Study of T-PRED(TM) Compared to Pred Forte(R)
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
Worked on PRED FORTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PRED FORTE offers limited growth opportunity; roles focus on defensive market management, generic transition planning, and maintaining existing market share in a mature ophthalmology segment. Career development is constrained by product maturity and approaching loss of exclusivity, making this a consolidation rather than expansion opportunity.